Novartis secures new approval in China for Cosentyx (secukinumab) in pediatric psoriasis

  • China National Medical Products Administration (NMPA) approval reinforces that Cosentyx (secukinumab) is safe and effective for children and adults with psoriasis
  • Moderate-to-severe plaque psoriasis affects more than 350,000 children worldwide1, with the physical and psychological burden disrupting important formative years2
  • Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions3-5 and with more than 500,000 patients treated worldwide since launch6
  • Approval in China for pediatric psoriasisácombined with recent filings in the United States and Europe for juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) further supports plans to expand Cosentyx to 10 indications over the next 10 years


Basel, August 17,á2021 - Novartis today announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (six years and older with a body weight

This site uses cookies and analysis tools to improve the usability of the site. More information. |